Safety of Flibanserin Versus Placebo in Women Taking a Selective Serotonin Reuptake Inhibitor or Norepinephrine Serotonin Reuptake Inhibitor With Decreased Sexual Desire.
Phase of Trial: Phase III
Latest Information Update: 01 Sep 2016
At a glance
- Drugs Flibanserin (Primary)
- Indications Anxiety disorders; Depressive disorders; Premenstrual dysphoric disorder
- Focus Adverse reactions; Registrational
- Sponsors Sprout Pharmaceuticals
- 22 May 2013 Results presented at the 166th Annual Meeting of the American Psychiatric Association.
- 02 Mar 2012 Sprout Pharmaceuticals as company and lead trial centre added as reported by ClinicalTrials.gov.
- 18 Oct 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History